Transplant and Cellular Therapy Program
The Transplant and Cellular Therapy Program is conducted in conjunction with the Rutgers Cancer Institute of New Jersey. The team performs stem cell transplants for patients with a variety of illnesses:
- Acute and chronic leukemias
- Myelodysplasia
- Various types of lymphoma
- Hodgkin's disease
- Multiple myeloma
- Amyloidosis and related diseases
Both autologous and allogeneic transplants are performed.
The sources of transplant include matched siblings as well as matched unrelated donors and umbilical cord blood. There are several research initiatives within the Transplant and Cellular Therapy program. In addition to participating in national and international clinical research studies with other transplant centers, there are unique research programs focusing on novel ways to: prevent graft-versus-host disease; improve umbilical cord blood transplants; and develop novel cellular therapies with less toxicity than standard transplants.
The program is certified by FACT as well as the National Marrow Donor Program.
